Hepatocellular Carcinoma Excellence Forum

Hepatocellular Carcinoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Christopher Manz, MD, MSPH, Dana-Farber Cancer Institute

Videos

Treatment Patterns for Hepatocellular Carcinoma

12/18/2024

Christopher Manz, MD, MSHP, discusses results from a retrospective study evaluating the evolving treatment patterns for hepatocellular carcinoma.

Christopher Manz, MD, MSHP,...

12/18/2024

Oncology

Riccardo Lencioni, MD, University of Pisa School of Medicine

Videos

Addition of Durvalumab, Bevacizumab to TACE for Hepatocellular Carcinoma Improves PFS

01/23/2024

Riccardo Lencioni , MD;

Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.

Ricardo Lencioni, MD, shares...

01/23/2024

Oncology

Quiz

STRIDE vs Sorafenib for Unresectable Hepatocellular Carcinoma

10/05/2023

Which treatment was associated with a better chance of survival at 4 years for patients with unresectable hepatocellular carcinoma?

Which treatment was associated...

10/05/2023

Oncology

Bruno Sangro, MD, PhD, Clínica Universidad de Navarra

Videos

Long-Term OS Benefit of STRIDE Regimen Among Patients With Unresectable Hepatocellular Carcinoma

08/21/2023

Bruno Sangro , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Bruno Sangro, MD, PhD, discusses 4-year overall survival results from the phase 3 HIMALYA study.

At the 2023 World Congress on...

08/21/2023

Oncology

Laura Dawson, MD, Princess Margaret Cancer Center

Videos

Stereotactic Body Radiotherapy Plus Sorafenib Improved Survival Outcomes for Patients With Hepatocellular Carcinoma Compared to Sorafenib Alone

01/20/2023

At the 2023 ASCO Gastrointestinal Symposium, Laura Dawson, MD, shares updated data from the NRG/RTOG 1112 trial evaluating stereotactic body radiotherapy plus sorafenib compared with sorafenib for hepatocellular carcinoma.

At the 2023 ASCO...

01/20/2023

Oncology

Videos

Palliative Radiotherapy Improves Pain for Patients With Symptomatic Hepatocellular Carcinoma and Liver Metastases

01/20/2023

At the 2023 ASCO Gastrointestinal Symposium, Laura Dawson, MD, shares results from a study evaluating palliative radiotherapy for hepatocellular carcinoma and liver metastases.

At the 2023 ASCO...

01/20/2023

Oncology

Andrea Casadei-Gardini, MD, San Raffaele Hospital

Videos

Lenvatinib Demonstrates Significant Benefit vs Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

07/02/2022

Andrea Casadei-Gardini, MD, discusses findings from an international study examining atezolizumab plus bevacizumab vs lenvatinib or sorafenib in patients with non-viral unresectable hepatocellular carcinoma.

Andrea Casadei-Gardini, MD,...

07/02/2022

Oncology

Videos

Liver Transplant Associated With Improved OS vs Systemic Therapy Alone for Non-Metastatic Hepatocellular Carcinoma

07/02/2022

Firas Baidoun, MD, discusses findings from a study that compared survival outcomes between upfront liver transplant, liver transplant with bridge systemic therapy, and systemic therapy only, for non-metastatic hepatocellular carcinoma.

Firas Baidoun, MD, discusses...

07/02/2022

Oncology

Videos

Integrating New Agents into the Treatment of HCC

08/12/2020

Ghassan Abou-Alfa, MD, discusses integrating novel agents into treatment of hepatocellular carcinoma at the virtual 2020 ESMO World GI meeting.

Ghassan Abou-Alfa, MD, discusses...

08/12/2020

Oncology

Videos

Systemic and Local Therapy Updates in HCC

07/09/2020

Ghassan Abou-Alfa, MD, discusses systemic and local therapy updates in hepatocellular carcinoma in the third part of this interview highlighting abstracts of note presented at the virtual 2020 ASCO Annual Meeting.

Ghassan Abou-Alfa, MD, discusses...

07/09/2020

Oncology

Recent News

News

Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer

01/17/2025

Allison Casey ;

The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...

The US Food and Drug...

01/17/2025

Oncology

FDA Alerts

Sotorasib Plus Panitumumab Approved for Patients With KRAS G12C-Mutated Colorectal Cancer

01/17/2025

Stephanie Holland ;

Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.

Based on results from the phase...

01/17/2025

Oncology

FDA Approval

FDA Approves Acalabrutinib With Bendamustine and Rituximab for Patients With Previously Untreated MCL

01/17/2025

Gina Tomaine ;

The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.

The FDA granted approval to...

01/17/2025

Oncology

News

Presence of Circulating Lymphoma Cells May Be Associated With Worse Survival Outcomes for Newly Diagnosed Patients With DLBCL

01/16/2025

Emily Estrada ;

Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.

Inferior survival outcomes are...

01/16/2025

Oncology

News

Ciltacabtagene Autoleucel Demonstrates Efficacy for Patients With R/R Multiple Myeloma in Real-World Population

01/15/2025

Emily Estrada ;

Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.

Treatment with ciltacabtagene...

01/15/2025

Oncology

News

Addition of Nab-Paclitaxel to Standard Gemcitabine and Cisplatin Did Not Significantly Improve Survival for Patients With Newly Diagnosed Biliary Tract Cancer

01/14/2025

Stephanie Holland ;

According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.

According to results from the...

01/14/2025

Oncology

News

First-line Eribulin Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer

01/14/2025

Stephanie Holland ;

According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.

According to results from the...

01/14/2025

Oncology

News

Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma

01/08/2025

Stephanie Holland ;

Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.

Final results from the phase 3...

01/08/2025

Oncology

News

Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

01/08/2025

Stephanie Holland ;

According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.

According to results from the...

01/08/2025

Oncology

News

Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer

01/06/2025

Stephanie Holland ;

Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...

Interim analysis results from...

01/06/2025

Oncology